Protein Expression of Folate Receptor Alpha in Adenoid Cystic Carcinoma of the Head and Neck

References

• Bradley PJ. Adenoid cystic carcinoma evaluation and management: progress with optimism! Curr Opin Otolaryngol Head Neck Surg. 2017;25(2):147–153. doi:10.1097/MOO.0000000000000347
   PubMed Web of Science ®Google Scholar
• Coca-Pelaz A, Rodrigo JP, Bradley PJ, et al. Adenoid cystic carcinoma of the head and neck - an update. Oral Oncol. 2015;51(7):652–661. doi:10.1016/j.oraloncology.2015.04.005
   PubMed Web of Science ®Google Scholar
• Lorini L, Ardighieri L, Bozzola A, et al. Prognosis and management of recurrent and/or metastatic head and neck adenoid cystic carcinoma. Oral Oncol. 2021;115:105213. doi:10.1016/j.oraloncology.2021.105213
   PubMed Web of Science ®Google Scholar
• Dillon PM, Chakraborty S, Moskaluk CA, Joshi PJ, Thomas CY. Adenoid cystic carcinoma: a review of recent advances, molecular targets, and clinical trials. Head Neck. 2016;38(4):620–627. doi:10.1002/hed.23925
   PubMed Web of Science ®Google Scholar
• Scaranti M, Cojocaru E, Banerjee S, Banerji U. Exploiting the folate receptor α in oncology. Nat Rev Clin Oncol. 2020;17(6):349–359. doi:10.1038/s41571-020-0339-5
   PubMed Web of Science ®Google Scholar
• Cheung A, Bax HJ, Josephs DH, et al. Targeting folate receptor alpha for cancer treatment. Oncotarget. 2016;7(32):52553–52574. doi:10.18632/oncotarget.9651
   PubMedGoogle Scholar
• Birrer MJ, Betella I, Martin LP, Moore KN. Is targeting the folate receptor in ovarian cancer coming of age? Oncologist. 2019;24(4):425–429. doi:10.1634/theoncologist.2018-0459
   PubMed Web of Science ®Google Scholar
• Markert S, Lassmann S, Gabriel B, et al. Alpha-folate receptor expression in epithelial ovarian carcinoma and non-neoplastic ovarian tissue. Anticancer Res. 2008;28(6A):3567–3572.
   PubMed Web of Science ®Google Scholar
• Köbel M, Madore J, Ramus SJ, et al. Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An ovarian tumour tissue analysis consortium study. Br J Cancer. 2014;111(12):2297–2307. doi:10.1038/bjc.2014.567
   PubMed Web of Science ®Google Scholar
• Kalli KR, Oberg AL, Keeney GL, et al. Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol. 2008;108(3):619–626. doi:10.1016/j.ygyno.2007.11.020
   PubMed Web of Science ®Google Scholar
• O’Shannessy DJ, Yu G, Smale R, et al. Folate receptor alpha expression in lung cancer: diagnostic and prognostic significance. Oncotarget. 2012;3(4):414–425. doi:10.18632/oncotarget.519
   PubMedGoogle Scholar
• Bremer RE, Scoggin TS, Somers EB, O’Shannessy DJ, Tacha DE. Interobserver agreement and assay reproducibility of folate receptor α expression in lung adenocarcinoma: a prognostic marker and potential therapeutic target. Arch Pathol Lab Med. 2013;137(12):1747–1752. doi:10.5858/arpa.2013-0039-OA
   PubMed Web of Science ®Google Scholar
• Zagorac I, Lončar B, Dmitrović B, Kralik K, Kovačević A. Correlation of folate receptor alpha expression with clinicopathological parameters and outcome in triple negative breast cancer. Ann Diagn Pathol. 2020;48:151596. doi:10.1016/j.anndiagpath.2020.151596
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/results?term=folate+receptor+alpha&Search=Apply&age_v=&gndr=&type=Intr&rslt=. Accessed May 10, 2022.
   Google Scholar
• O’Malley DM, Matulonis UA, Birrer MJ, et al. Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. Gynecol Oncol. 2020;157(2):379–385. doi:10.1016/j.ygyno.2020.01.037
   PubMed Web of Science ®Google Scholar
• Shimizu T, Fujiwara Y, Yonemori K, et al. First-in-human Phase 1 study of MORAb-202, an antibody–Drug conjugate comprising farletuzumab linked to Eribulin Mesylate, in patients with folate receptor-a–Positive advanced solid tumors. Clin Cancer Res. 2021;27(14):3905–3915. doi:10.1158/1078-0432.CCR-20-4740
   PubMed Web of Science ®Google Scholar
• Moore KN, Vergote I, Oaknin A, et al. FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer. Futur Oncol. 2018;14(17):1669–1678. doi:10.2217/fon-2017-0646
   PubMed Web of Science ®Google Scholar
• Moore KN, Oza AM, Colombo N, et al. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. Ann Oncol. 2021;32(6):757–765. doi:10.1016/j.annonc.2021.02.017
   PubMed Web of Science ®Google Scholar
• Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17(4):343–346. doi:10.1016/0197-2456(96)00075-X
   PubMedGoogle Scholar
• Desai A, Sequeira JM, Quadros EV. The metabolic basis for developmental disorders due to defective folate transport. Biochimie. 2016;126:31–42. doi:10.1016/j.biochi.2016.02.012
   PubMed Web of Science ®Google Scholar
• Naumann RW, Coleman RL, Burger RA, et al. PRECEDENT: a randomized Phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2013;31(35):4400–4406. doi:10.1200/JCO.2013.49.7685
   PubMed Web of Science ®Google Scholar
• Ab O, Whiteman KR, Bartle LM, et al. IMGN853, a folate receptor-α (FRα)-targeting antibody-drug conjugate, exhibits potent targeted antitumor activity against FRα-expressing tumors. Mol Cancer Ther. 2015;14(7):1605–1613. doi:10.1158/1535-7163.MCT-14-1095
   PubMed Web of Science ®Google Scholar
• Weitman SD, Lark RH, Coney LR, et al. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res. 1992;52(12):3396–3401.
   PubMed Web of Science ®Google Scholar
• Gnesin S, Müller J, Burger IA, et al. Radiation dosimetry of 18F-AzaFol: a first in-human use of a folate receptor PET tracer. EJNMMI Res. 2020;10(1). doi:10.1186/s13550-020-00624-2
   Web of Science ®Google Scholar